Skip to main content

#Influenza and Other Respiratory Viruses Research #References (by AMEDEO, March 1 '25)

Image
By G.M.



    BMC Pediatr

  1. MEHDIZADEGAN N, Omidbakhsh S, Shorafa E, Hosseini H, et al
    Speckle-tracking and conventional echocardiography in MIS-C: tracking cardiac involvement and recovery.
    BMC Pediatr. 2025;25:137.
    PubMed         Abstract available


    BMJ

  2. MACINTYRE CR, Chughtai AA, Kunasekaran M, Tawfiq E, et al
    The role of masks and respirators in preventing respiratory infections in healthcare and community settings.
    BMJ. 2025;388:e078573.
    PubMed         Abstract available


    Epidemiol Infect

  3. LIN W, Kung KH, Chan CL, Chuang SK, et al
    Characteristics and risk factors associated with COVID-19 reinfection in Hong Kong: a retrospective cohort study.
    Epidemiol Infect. 2025;153:e30.
    PubMed         Abstract available

  4. HOEVE CE, Neppelenbroek N, Vos ERA, Huiberts AJ, et al
    Using SARS-CoV-2 nucleoprotein antibodies to detect (re)infection.
    Epidemiol Infect. 2025;153:e38.
    PubMed         Abstract available

  5. PASCULLI P, Antonacci M, Zingaropoli MA, Dominelli F, et al
    SARS-CoV-2 vaccination influence in the development of long-COVID clinical phenotypes.
    Epidemiol Infect. 2025;153:e40.
    PubMed         Abstract available

  6. TYRRELL GJ, Croxen M, McCullough E, Li V, et al
    Group A streptococcal infections in Alberta, Canada 2018-2023.
    Epidemiol Infect. 2024;153:e35.
    PubMed         Abstract available


    J Infect Dis

  7. HUANG QS, Wood T, Aminisani N, Kvalsvig A, et al
    Comparison of the incidence and risk factors of COVID-19 and influenza associated acute respiratory illnesses: Results of the SHIVERS-II, III, IV prospective community cohort study.
    J Infect Dis. 2025 Feb 24:jiaf097. doi: 10.1093.
    PubMed         Abstract available


    J Virol

  8. GUNAWARDENE CD, Wong L-YR
    Betacoronavirus internal protein: role in immune evasion and viral pathogenesis.
    J Virol. 2025 Jan 6:e0135324. doi: 10.1128/jvi.01353.
    PubMed         Abstract available

  9. HU H, Leng C, Shu Y, Peng L, et al
    Structural insights into hybridoma-derived neutralizing monoclonal antibodies against Omicron BA.5 and XBB.1.16 variants of SARS-CoV-2.
    J Virol. 2025 Jan 7:e0130724. doi: 10.1128/jvi.01307.
    PubMed         Abstract available

  10. ARORA P, Zhang L, Nehlmeier I, Kempf A, et al
    Host cell lectins ASGR1 and DC-SIGN jointly with TMEM106B confer ACE2 independence and imdevimab resistance to SARS-CoV-2 pseudovirus with spike mutation E484D.
    J Virol. 2025 Jan 10:e0123024. doi: 10.1128/jvi.01230.
    PubMed         Abstract available

  11. CAI C, Pham TNQ, Adam D, Brochiero E, et al
    Sensing of SARS-CoV-2-infected cells by plasmacytoid dendritic cells is modulated via an interplay between CD54/ICAM-1 and CD11a/LFA-1 alpha(L) integrin.
    J Virol. 2025 Jan 13:e0123524. doi: 10.1128/jvi.01235.
    PubMed         Abstract available

  12. NAGHIBOSADAT M, Babuadze GG, Pei Y, Hurst J, et al
    Vaccination against SARS-CoV-2 provides low-level cross-protection against common cold coronaviruses in mouse and non-human primate animal models.
    J Virol. 2025 Jan 16:e0139024. doi: 10.1128/jvi.01390.
    PubMed         Abstract available

  13. MILLER JL, Leedale C, Kang D, Lilue J, et al
    Prostaglandin D2 delays CD8+ T-cell responses and respiratory syncytial virus clearance in geriatric cotton rats.
    J Virol. 2025;99:e0186324.
    PubMed         Abstract available

  14. QU X, Zhu Z, Zhou X, Wu X, et al
    KRT9 is required for GBP5 suppression of human respiratory syncytial virus.
    J Virol. 2025;99:e0202924.
    PubMed         Abstract available

  15. WANG Y, Xia B, Gao Z
    A comprehensive review of current insights into the virulence factors of SARS-CoV-2.
    J Virol. 2025 Jan 29:e0204924. doi: 10.1128/jvi.02049.
    PubMed         Abstract available

  16. LYTRAS S, Lamb KD, Ito J, Grove J, et al
    Pathogen genomic surveillance and the AI revolution.
    J Virol. 2025 Jan 29:e0160124. doi: 10.1128/jvi.01601.
    PubMed         Abstract available

  17. HAO T, Xie Y, Chai Y, Zhang W, et al
    Structural basis of receptor-binding adaptation of human-infecting H3N8 influenza A virus.
    J Virol. 2025 Feb 24:e0106524. doi: 10.1128/jvi.01065.
    PubMed         Abstract available


    JAMA

  18. GENG LN, Erlandson KM, Hornig M, Letts R, et al
    2024 Update of the RECOVER-Adult Long COVID Research Index.
    JAMA. 2024 Dec 18. doi: 10.1001/jama.2024.24184.
    PubMed         Abstract available


    MMWR Morb Mortal Wkly Rep

  19. FRUTOS AM, Cleary S, Reeves EL, Ahmad HM, et al
    Interim Estimates of 2024-2025 Seasonal Influenza Vaccine Effectiveness - Four Vaccine Effectiveness Networks, United States, October 2024-February 2025.
    MMWR Morb Mortal Wkly Rep. 2025;74:83-90.
    PubMed         Abstract available

  20. FAZAL A, Reinhart K, Huang S, Kniss K, et al
    Reports of Encephalopathy Among Children with Influenza-Associated Mortality - United States, 2010-11 Through 2024-25 Influenza Seasons.
    MMWR Morb Mortal Wkly Rep. 2025;74:91-95.
    PubMed         Abstract available

  21. FALENDER R, Radniecki TS, Kelly C, Cieslak P, et al
    Avian Influenza A(H5) Subtype in Wastewater - Oregon, September 15, 2021-July 11, 2024.
    MMWR Morb Mortal Wkly Rep. 2025;74:102-106.
    PubMed         Abstract available

  22. LINK-GELLES R, Chickery S, Webber A, Ong TC, et al
    Interim Estimates of 2024-2025 COVID-19 Vaccine Effectiveness Among Adults Aged >/=18 Years - VISION and IVY Networks, September 2024-January 2025.
    MMWR Morb Mortal Wkly Rep. 2025;74:73-82.
    PubMed         Abstract available


    PLoS Comput Biol

  23. BANHOLZER N, Middelkoop K, Leukes J, Weingartner E, et al
    Estimating Mycobacterium tuberculosis transmission in a South African clinic: Spatiotemporal model based on person movements.
    PLoS Comput Biol. 2025;21:e1012823.
    PubMed         Abstract available


    PLoS Med

  24. RAZIEH C, Powell B, Drummond R, Ward IL, et al
    Understanding the quality of ethnicity data recorded in health-related administrative data sources compared with Census 2021 in England.
    PLoS Med. 2025;22:e1004507.
    PubMed         Abstract available


    PLoS One

  25. MACHADO-VIEIRA R, Krause TM, Jones G, Teixeira AL, et al
    Protective effects of psychiatric medications against COVID-19 mortality before vaccines.
    PLoS One. 2025;20:e0310438.
    PubMed         Abstract available

  26. BILLANY RE, Macdonald JH, Burns S, Chowdhury R, et al
    A structured, home-based exercise programme in kidney transplant recipients (ECSERT): A randomised controlled feasibility study.
    PLoS One. 2025;20:e0316031.
    PubMed         Abstract available

  27. SHABAN RZ, Curtis K, Fry M, McCormack B, et al
    Protocol to establish standards for the elements infection prevention and control programs and competencies for infection control professionals in Australian residential aged care homes.
    PLoS One. 2025;20:e0319108.
    PubMed         Abstract available

  28. KESSELS R, Gotwalt C, Erreygers G
    Revisiting Pearl's influenza studies by bootstrapping for forward variable selection with a null factor.
    PLoS One. 2025;20:e0318685.
    PubMed         Abstract available

  29. AHMAD A, Majaz S, Saeed A, Noreen S, et al
    Microevolution and phylogenomic study of Respiratory Syncytial Virus type A.
    PLoS One. 2025;20:e0319437.
    PubMed         Abstract available

  30. MAREE G, Els F, Naidoo Y, Naidoo L, et al
    Wastewater surveillance overcomes socio-economic limitations of laboratory-based surveillance when monitoring disease transmission: The South African experience during the COVID-19 pandemic.
    PLoS One. 2025;20:e0311332.
    PubMed         Abstract available

  31. BALSOM AA, Dube L, Gordon JL
    What women want to hear: the helpful and unhelpful comments reported by women struggling with infertility amidst the COVID-19 pandemic.
    PLoS One. 2025;20:e0318921.
    PubMed         Abstract available

  32. OTAKI F, Ho SB, Nair B, AlGurg R, et al
    Effects of building resilience skills among undergraduate medical students in a multi-cultural, multi-ethnic setting in the United Arab Emirates: A convergent mixed methods study.
    PLoS One. 2025;20:e0308774.
    PubMed         Abstract available

  33. O'BRIEN KK, Brown DA, McDuff K, St Clair-Sullivan N, et al
    Episodic disability framework in the context of Long COVID: Findings from a community-engaged international qualitative study.
    PLoS One. 2025;20:e0305187.
    PubMed         Abstract available

  34. GHEZZAWI M, Fahme S, Al Sabbagh R, Naalbandian S, et al
    Impact of the COVID-19 pandemic on women in the workplace in the Middle East and North Africa: A scoping review protocol.
    PLoS One. 2025;20:e0312037.
    PubMed         Abstract available

  35. NUGENT JR, Wood MS, Liu L, Bullick T, et al
    SARS-CoV-2 Omicron subvariant genomic variation associations with immune evasion in Northern California: A retrospective cohort study.
    PLoS One. 2025;20:e0319218.
    PubMed         Abstract available


    Proc Natl Acad Sci U S A

  36. SCHNYDER SK, Molina JJ, Yamamoto R, Turner MS, et al
    Understanding Nash epidemics.
    Proc Natl Acad Sci U S A. 2025;122:e2409362122.
    PubMed         Abstract available


    Vaccine

  37. SHEERAH HA, Al-Jedai AH, Al-Jerian NA, Al-Otaiby MA, et al
    COVID-19 and influenza hospitalizations and the role of COVID-19 vaccination in the post-pandemic period: A cross-sectional study from Saudi Arabia.
    Vaccine. 2025;52:126937.
    PubMed         Abstract available

  38. FARAH Z, Bazant ES, Basha I, Saleh N, et al
    Determinants of seasonal influenza vaccination uptake, intention and recommendations among Lebanese physicians.
    Vaccine. 2025;52:126890.
    PubMed         Abstract available

  39. YE Q, Xiao Z, Bai C, Yao H, et al
    Unveiling the multi-characteristic potential of hyper-productive suspension MDCK cells for advanced influenza A virus propagation.
    Vaccine. 2025;52:126900.
    PubMed         Abstract available

  40. DARWAR R, Huang X, Abayeneh A, Alemayehu Beshah S, et al
    Costing approaches for vaccine-preventable disease surveillance: Lessons from Ethiopia and Nepal.
    Vaccine. 2025;50:126776.
    PubMed         Abstract available

  41. COTUGNO N, Sanna M, Amodio D, Morrocchi E, et al
    Pre-vaccination immune markers predict response to BNT162b2 mRNA vaccine in vulnerable groups - The CONVERS project, report from a pediatric tertiary hospital.
    Vaccine. 2025;49:126778.
    PubMed         Abstract available

  42. SHARMA A, Kerkhoff AD, Haambokoma M, Shamoya B, et al
    Intention to receive new vaccines post-COVID-19 pandemic among adults and health workers in Lusaka, Zambia.
    Vaccine. 2025;50:126846.
    PubMed         Abstract available

  43. CAPAO A, Araujo MF, Tort LFL, Toledo TS, et al
    Impact in the humoral and cellular immune response to SARS-CoV-2 variants after primary vaccination with AZD1222/COVISHIELD protocol in healthy adults.
    Vaccine. 2025;50:126785.
    PubMed         Abstract available

  44. SHINO MY, Ibarrondo FJ, Yang OO
    SARS-CoV-2 spike antibody levels in lung transplantation recipients versus the spectrum in non-immunocompromised persons.
    Vaccine. 2025;50:126851.
    PubMed         Abstract available

  45. FU Y, Xu Z, Wang Q, Zhang J, et al
    Effectiveness and coverage of COVID-19 vaccination among the infection-naive population: A community-based retrospective cohort study in China.
    Vaccine. 2025;50:126836.
    PubMed         Abstract available

  46. VAHORA MS, Leao O, da Silveira MF, Domingues MR, et al
    Impacts of vaccination, school attendance, and nutrition on SARS-CoV-2 antibody titer in a prospective birth cohort in Brazil.
    Vaccine. 2025;49:126838.
    PubMed         Abstract available

  47. MCCLYMONT E, Wong JMH, Forward L, Blitz S, et al
    Acceptance and preference between respiratory syncytial virus vaccination during pregnancy and infant monoclonal antibody among pregnant and postpartum persons in Canada.
    Vaccine. 2025;50:126818.
    PubMed         Abstract available

  48. KANG HS, Kim SY, De Gagne JC, Chae SM, et al
    Pregnant women's experiences of and attitudes toward COVID-19 vaccination: A qualitative descriptive study.
    Vaccine. 2025;50:126835.
    PubMed         Abstract available

  49. LAO G, Feng J, Wu L, Su W, et al
    Development of a genetically modified full-length human respiratory syncytial virus preF protein vaccine.
    Vaccine. 2025;49:126799.
    PubMed         Abstract available

  50. ITO S, Tsuchida N, Kusunoki S, Kaneko Y, et al
    Safety comparison between Pfizer BNT162b2, Moderna mRNA-1273, and AstraZeneca AZD1222 in a Nationwide prospective cohort survey at the beginning of the severe acute respiratory syndrome coronavirus 2 vaccination in Japan.
    Vaccine. 2025;49:126754.
    PubMed         Abstract available

  51. WIEGAND RE, Devine O, Wallace M, Ortega-Sanchez IR, et al
    Estimating COVID-19 associated hospitalizations, ICU admissions, and in-hospital deaths averted in the United States by 2023-2024 COVID-19 vaccination: A conditional probability, causal inference, and multiplier-based approach.
    Vaccine. 2025;49:126808.
    PubMed         Abstract available

  52. JI C, Senthinathan A, Apajee J, Dubey V, et al
    Impact of the COVID-19 pandemic on routine immunization coverage of children and teenagers in Ontario, Canada.
    Vaccine. 2025;49:126811.
    PubMed         Abstract available

  53. YILMAZ IC, Ipekoglu EM, Golcuklu BS, Bildik T, et al
    A phase I/II study of CpG/alum-adjuvanted mammalian-derived quadruple antigen carrying virus-like particle COVID-19 vaccine.
    Vaccine. 2025;49:126787.
    PubMed         Abstract available

  54. GRAILEY K, Crespo RF, Woldmann L, Chisambi M, et al
    Implementing behavioural science-informed letter interventions to increase COVID-19 vaccination uptake in London residents. A difference-in-difference study in London, United Kingdom.
    Vaccine. 2025;49:126781.
    PubMed         Abstract available

  55. GSCHWEND MH, Marchese AM, Poelaert D, Warren B, et al
    Efficacy, immunogenicity, and safety of the Novavax COVID-19 vaccine in immunocompromised patients: A targeted literature review.
    Vaccine. 2025;49:126777.
    PubMed         Abstract available

  56. MCGOLDRICK M, Truong TBQ, Campa C, Ali M, et al
    How to accelerate the supply of vaccines to all populations worldwide? Part III: Reflections after the pandemic.
    Vaccine. 2025;49:126782.
    PubMed         Abstract available

  57. KAN AKC, Mak HWF, Chiang V, Yim JSH, et al
    Leveraging COVID-19 vaccine allergy evaluations with coincident drug allergy delabelling: Effectiveness and impact on quality of life.
    Vaccine. 2025;50:126849.
    PubMed         Abstract available

  58. DOUA J, Ndembi N, Auerbach J, Kaseya J, et al
    Advancing local manufacturing capacities for vaccines within Africa - Opportunities, priorities and challenges.
    Vaccine. 2025;50:126829.
    PubMed         Abstract available

  59. HONDA-OKUBO Y, Sajkov D, Wauchope B, Turner JV, et al
    Immunogenicity and safety study of a single dose of SpikoGen(R) vaccine as a heterologous or homologous intramuscular booster following a primary course of mRNA, adenoviral vector or recombinant protein COVID-19 vaccine in ambulatory adults.
    Vaccine. 2025;49:126744.
    PubMed         Abstract available


    Virology

  60. HARADA R, Hiono T, Igarashi M, Kobayashi D, et al
    Altered receptor-binding specificity of gull-adapted H13 avian influenza viruses corresponds to their unique host preferences.
    Virology. 2025;605:110460.
    PubMed         Abstract available

 

Labels:

Comments

Post a Comment

Popular posts from this blog

#Neuroinvasive #Oropouche virus in a patient with #HIV from extra-Amazonian #Brazil

By G.M.
{Excerpt} A novel reassortant Oropouche virus (OROV) lineage (with medium [M], large [L], and small [S] RNA segments : M1L2S2) has driven Brazil's largest and most geographically widespread OROV epidemic , expanding beyond the endemic Amazon basin to establish local transmission across multiple Brazilian states and other previously unaffected Latin American countries . The rapid spread of this lineage underscores its evolutionary potential and reinforces its significance as a public health threat .1 Similar to chikungunya and Zika viruses, expanding arboviruses can exhibit unexpected clinical and epidemiological shifts , including vertical transmissions , neuroinvasive effects, and potentially fatal outcomes.2–4 Although OROV typically causes self-limited febrile illness, accumulating clinical and experimental evidence suggests neurotropic potential .5 This Correspondence describes the first confirmed case of neuroinvasive OROV infection caused by the emergent M1L2S2 lineage in ext...
Post a Comment
Read more »

No evidence of immune #exhaustion after repeated #SARS-CoV-2 #vaccination in vulnerable and healthy populations

By G.M.
Abstract Frequent SARS-CoV-2 vaccination in vulnerable populations has raised concerns that this may contribute to T cell exhaustion , which could negatively affect the quality of immune protection. Herein, we examined the impact of repeated SARS-CoV-2 vaccination on T cell phenotypic and functional exhaustion in frail older adults in long-term care (n = 23), individuals on immunosuppressive drugs (n = 10), and healthy adults (n = 43), in Canada . Spike-specific CD4+ and CD8+ T cell levels did not decline in any cohort following repeated SARS-CoV-2 vaccination, nor did the expression of exhaustion markers on spike-specific or total T cells increase. T cell production of multiple cytokines (i.e. polyfunctionality) in response to the spike protein of SARS-CoV-2 did not decline in any cohort following repeated vaccination. None of the cohorts displayed elevated levels of terminally differentiated T cells following multiple SARS-CoV-2 vaccinations. Thus, repeated SARS-CoV-2 vaccination was...
Post a Comment
Read more »

Chimeric #hemagglutinin and #M2 #mRNA #vaccine for broad #influenza subtype protection

By G.M.
Abstract Since multiple and unpredicted influenza viruses cause seasonal epidemics and even high-risk pandemics , developing a universal influenza vaccine is essential to provide broad protection against various influenza subtypes. Combined with the mRNA lipid nanoparticle-encapsulated (mRNA-LNP) vaccine platform and chimeric immunogen strategy , we developed a novel cocktail mRNA vaccine encoding chimeric HAs (cH5/1-BV, cH7/3) and intact M2 (termed Fluaxe), which confers broad protection against major circulating IAVs and IBVs , as well as highly pathogenic avian influenza . Two-dose intramuscular immunization of Fluaxe in mice elicited cross-reactive neutralizing antibodies , T cell responses, and long-lived immunity, resulting in robust protection against multiple lethal influenza virus infections and severe acute lung injuries . In particular, intramuscular administration stimulated systemic immunity together with a prominent lung tropism of memory cells . Moreover, Fluaxe immuniza...
Post a Comment
Read more »